Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew C Hsieh

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
The Journal of Clinical Investigation|July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerMark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Nature Communications|November 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancerShankha S Chatterjee, Juan F Linares, Tania Cid-Diaz, et al.
Clinical Genitourinary Cancer|November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) ProgramLeonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
Science Translational Medicine|August 2, 2019
The androgen receptor regulates a druggable translational regulon in advanced prostate cancerYuzhen Liu, Jessie L Horn, Kalyan Banda, et al.
Cancer Cell|April 21, 2023
Transcriptional-translational conflict is a barrier to cellular transformation and cancer progressionSujata Jana, Sandipan Brahma, Sonali Arora, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Clinical Genitourinary Cancer|May 7, 2023
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical CystectomyRishi R Sekar, Leonidas N Diamantopoulos, Dimitra R Bakaloudi, et al.
Urologic Oncology|May 2, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotypingDana Cavanaugh, Sarah K Holt, Erin Dwyer, et al.
European Urology|August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 TrialRuben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Urologic Oncology|September 3, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort studyDimitra Rafailia Bakaloudi, Elizabeth L Koehne, Jenna M Voutsinas, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Investigation|July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancerMark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Nature Communications|November 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancerShankha S Chatterjee, Juan F Linares, Tania Cid-Diaz, et al.
Clinical Genitourinary Cancer|November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) ProgramLeonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
Science Translational Medicine|August 2, 2019
The androgen receptor regulates a druggable translational regulon in advanced prostate cancerYuzhen Liu, Jessie L Horn, Kalyan Banda, et al.
Cancer Cell|April 21, 2023
Transcriptional-translational conflict is a barrier to cellular transformation and cancer progressionSujata Jana, Sandipan Brahma, Sonali Arora, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Clinical Genitourinary Cancer|May 7, 2023
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical CystectomyRishi R Sekar, Leonidas N Diamantopoulos, Dimitra R Bakaloudi, et al.
Urologic Oncology|May 2, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotypingDana Cavanaugh, Sarah K Holt, Erin Dwyer, et al.
European Urology|August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 TrialRuben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Urologic Oncology|September 3, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort studyDimitra Rafailia Bakaloudi, Elizabeth L Koehne, Jenna M Voutsinas, et al.
Pageof 7